|Starting on :||05:30 PM 01 December, 2016||Venue:||The Karen Hospital -Resource centre 3rd floor|
|Ending on :||08:00 PM 01 December, 2016||Max Credits:||3.00|
|Moderator:||No Activity Moderator||Activity Cost:||0|
Following the results of the recent Phase III Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure clinical trial in patients with chronic HF with reduced ejection fraction (HF-REF), this review focuses on LCZ696 , a first-in-class angiotensin receptor NEP inhibitor.
-To define LCZ696
-To know the advantages ofLCZ696 in management of Heart failure